Antiva Biosciences Strengthens Leadership with Key New Appointments
REDWOOD CITY, Calif., Oct. 18, 2023 /PRNewswire/ -- Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of high-risk infections and pre-cancerous lesions caused by human papilloma virus (HPV), today announced several key new appointments designed to strengthen the company's leadership as it continues to advance its lead development candidate, ABI-2280. The company has added Elaine Chien, M.D., FACOG, as chief medical officer, Susan Wilson, Ph.D., as vice president of project management and strategic initiatives, and Rajashree Joshi-Hangal, Ph.D., as vice president of technical operations. Collectively, these individuals bring Antiva significant industry experience in areas directly related to the company's ongoing work in developing innovative treatments for diseases caused by HPV infection.
- Collectively, these individuals bring Antiva significant industry experience in areas directly related to the company's ongoing work in developing innovative treatments for diseases caused by HPV infection.
- "With the closing of our Series E financing earlier this year, Antiva entered an important new phase as we work to advance ABI-2280 into key efficacy studies across multiple indications.
- Antiva is currently working to advance ABI-2280 into key efficacy studies.
- She has also held positions of increasing managerial responsibilities in both technical and regulatory CMC areas at Astex Pharmaceuticals.